EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Concomitant medication in patients with bradykinin‐mediated angioedema – there's more than ACE inhibitors

Robin Lochbaum, Thomas K Hoffmann, Jens Greve, Janina Hahn

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023

DOI: 10.1111/ddg.15154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Robin Lochbaum und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oto-Rhino-Laryngology Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany. Hauptthemen laut MEDLINE: Angioedema, Angioedemas, Hereditary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bradykinin‐mediated angioedema is a rare, non‐allergic, potentially life‐threatening disease. ACE inhibitor‐induced angioedema and hereditary angioedema (HAE) are the two most common presentations. Therapeutic options, pathophysiology and diagnosis continue to be investigated, with considerable progress in HAE over the last few decades. For all patients with bradykinin‐mediated angioedema, there are several medications that should be avoided or administered with caution. Some of the triggering medications are well known, while others are suspected or of unknown significance. A common denominator is that there is no approved therapy for bradykinin‐mediated angioedema as a drug side effect. Some medications, such as tissue plasminogen activator, have a higher incidence of angioedema with potential airway compromise than ACE inhibitors, although this fact is widely underappreciated. In this review, we aim to summarize what is currently known and recommended about concomitant medication in HAE patients and the interaction of other bradykinin‐influencing drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AngioedemaAngioedemas, HereditaryHumansAngiotensin-Converting Enzyme InhibitorsBradykininTissue Plasminogen ActivatorComplement C1 Inhibitor Protein

Substanzen

Angiotensin-Converting Enzyme InhibitorsBradykininTissue Plasminogen ActivatorComplement C1 Inhibitor Protein

Autor:innen und Institutionen

  • Department of Oto-Rhino-Laryngology Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.

Zitieren

APA

Lochbaum, R., Hoffmann, T. K., Greve, J., & Hahn, J. (2023). Concomitant medication in patients with bradykinin‐mediated angioedema – there's more than ACE inhibitors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15154

Vancouver

Lochbaum R, Hoffmann TK, Greve J, Hahn J. Concomitant medication in patients with bradykinin‐mediated angioedema – there's more than ACE inhibitors. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.15154

BibTeX
@article{Lochbaum2023,
  author = {Lochbaum, Robin and Hoffmann, Thomas K and Greve, Jens and Hahn, Janina},
  title = {Concomitant medication in patients with bradykinin‐mediated angioedema – there's more than ACE inhibitors},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2023},
  doi = {10.1111/ddg.15154}
}
Kostenlos starten →